| Autor: |
Amer Hamadé, Bastien Woehl, Marjolaine Talbot, Naouel Bensalah, Pierre Michel, Golnaz Obringer, Michèle Lehn-Hogg, Nathalie Buschenrieder, Mahdi Issa, Jonathan Tousch, Dominique Stephan, Lucas Jambert |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Annals of Hepatology, Vol 21, Iss , Pp 100274- (2021) |
| Druh dokumentu: |
article |
| ISSN: |
1665-2681 |
| DOI: |
10.1016/j.aohep.2020.10.002 |
| Popis: |
Introduction and objectives: Since the outbreak of the COVID-19 pandemic, increasing evidence suggests that infected patients present a high incidence of venous thromboembolic (VTE) events and elevated aminotransferases (AT).The objective of this work was to evaluate the incidence of aminotransferases disorders in patients infected with COVID-19 and to manage the VTE events associated with elevated AT. Patients or Materials and methods: We report a retrospective study of 46 patients admitted for COVID-19 infection. Venous duplex ultrasound of lower limbs was performed in all patients at Day 0 and Day 5. All patients had antithrombotic-prophylaxis upon admission using low molecular weight heparin with Enoxaparin. Demographics, comorbidities and laboratory parameters were collected and analyzed. Results: Elevated AT were reported in 28 patients (61%). 10 had acute VTE events of which eight (17.4%) had aminotransferases disorders. They had been treated with curative Enoxaparin. After a follow-up of 15 and/or 30 days, six of them were controlled, and treated with direct oral anticoagulant (DOACs) after normalization of aminotransferases. Conclusions: The incidence of aminotransferases disorders associated with acute VTE events in patients infected with COVID-19 is significant. The use of DOACs appear pertinent in these patients. Monitoring of the liver balance should therefore be considered at a distance from the acute episode in the perspective of DOACs relay. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
